Breast Cancer
Breast Cancer
Advertisement
Nera Lopetegui-Lia, MDAdvancements in Oncology | June 14, 2024
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
View More
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 13, 2024
Dr. Margaret Gatti-Mays explains what makes The Oncology Brothers' content so important for community oncologists.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 14, 2024
Dr. Margaret Gatti-Mays explains how to address the most pressing questions in triple-negative breast cancer treatments.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 14, 2024
Dr. Gatti-Mays discusses how treatment for triple-negative breast cancer has evolved in recent years.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 12, 2024
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
Dr. Eric VachonBreast Cancer | June 11, 2024
A study examined the impact of relationship satisfaction and agreement between breast cancer survivors and their partners.
Dr. Margaret Gatti-MaysAdvancements in Oncology | June 12, 2024
Dr. Gatti-Mays talks about the importance of tailoring treatments to individual patients with breast cancer.
Rob DillardAdvancements in Oncology | June 7, 2024
Dr. Margaret Gatti-Mays, who specializes in breast cancer, delivers key insights on many breast cancer-related topics.
Rob DillardAdvancements in Oncology | June 6, 2024
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Rob DillardAdvancements in Oncology | June 6, 2024
Dr. Margaret Gatti-Mays details the treatment options for BC patients in the hormone receptor-positive metastatic setting.
Rob DillardASCO 2024 | June 6, 2024
Some patients are unaware that metastatic breast cancer is incurable and that their treatment has no established end date.
Rob DillardAdvancements in Oncology | June 6, 2024
The Oncology Brothers spoke with Dr. Margaret Gatti-Mays, who provided invaluable insights on hormone receptor-positive BC.
Rob DillardASCO 2024 | June 3, 2024
Eribulin is noninferior to trastuzumab and pertuzumab plus taxane in treating HER2-positive breast cancer.
Rob DillardASCO 2024 | June 3, 2024
Episodic future thinking may help breast cancer survivors lose weight.
Rob DillardASCO 2024 | May 31, 2024
Sexual health concerns are highly prevalent in women following breast cancer diagnosis.
Dr. Barbara SmithBreast Cancer | May 23, 2024
Barbara Smith, MD, PhD, discusses the Lumicell Direct Visualization System and how it can enhance breast cancer detection.
Rob DillardESMO Breast Cancer 2024 | May 16, 2024
The HER2DX ERBB2 mRNA score was significantly associated with improved survival in patients with metastatic HER2+ BC.
Rob DillardESMO Breast Cancer 2024 | May 16, 2024
Breast cancer survivors with metabolic syndrome have shorter disease-free survival than those without metabolic syndrome.
Rob DillardESMO Breast Cancer 2024 | May 15, 2024
Breast cancer survivors have a modestly increased risk of type 2 diabetes, largely driven by breast cancer treatment.
Rob DillardESMO Breast Cancer 2024 | May 15, 2024
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Advertisement
Advertisement
Advertisement
Latest News

June 20, 2024